We have previously shown that treatment with rapamycin extends mouse lifespan even when started as late as 20 months of age [31], suggesting that it may provide benefits related to mTOR action in growth or transformation of many different kinds of tumors, not just ovarian tumors. This evidence concerns the gene MTOR and ovarian neoplasm.